Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD) (CASL-AD-01)

University Hospital Bonn (UKB)

Status: Unknown

Conditions: Alzheimer's Disease

Treatments: Drug: Reminyl retard

Study type: Interventional

Funder types: Other

Identifiers

NCT00637442

University Bonn

Details and patient eligibility

About

Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease

Enrollment: 30 estimated patients

Sex: All

Ages: 50 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA
• Underwritten study consent
• No treatment with acetylcholinesterase inhibitors
• Mini-Mental-State Examination: 12-25 points
• Age: 50-80 Years
• Orale contraception for women of child-bearing age

Exclusion criteria

• Mental Disorders
• Other Diseases of the CNS
• Severe Illness
• Contraindication for MRI-Scan
• Contraindication for Galantamin (Reminyl retard®)
• Participation at other clinical trials

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

CASL-MRI

Experimental group

Description:

Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl

Treatment:

Drug: Reminyl retard